Why Competition Hasn't Brought Down The High Price Of Snakebite Treatment
The snakebite antivenin CroFab, on the U.S. market since 2000, now faces competition from a drug called Anavip. But both are expensive. "Perverse incentives" keep prices high, says one legal scholar.
Read more on NPR
August 8, 2019 at 04:00PM
Health Care
NPR News: Why Competition Hasn't Brought Down The High Price Of Snakebite Treatment
Posted by Unknown |
16:09
Related Posts:
NPR News: Should Hospitals Be Punished For Post-Surgical Patients' Opioid Addiction?Should Hospitals Be Punished For Post-Surgical Patients' Opioid Addiction? Many surgeons prescribe strong pain medicine without knowing how much their… Read More
NPR News: Can Paris Get Rid Of Gas-Fueled Cars?Can Paris Get Rid Of Gas-Fueled Cars? The mayor of Paris wants to rid the capital of all gas and diesel cars by the year 2030. But critics doubt the i… Read More
NPR News: The Fragmented Forests Of MadagascarThe Fragmented Forests Of Madagascar Madagascar is home to plants and animals found nowhere else, but their habitats are disappearing. The forest cove… Read More
NPR News: Studying Artificial Intelligence At New York UniversityStudying Artificial Intelligence At New York University New York University just opened an institute that studies the social implications of artificia… Read More
NPR News: Should Hospitals Be Punished For Post-Surgical Patients' Opioid Addiction?Should Hospitals Be Punished For Post-Surgical Patients' Opioid Addiction? Many surgeons prescribe strong pain medicine without knowing how much their… Read More
0 nhận xét:
Đăng nhận xét